Cytarabine

Essential medicine status

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc | ATC codes: L01BC01

Indication	Acute myeloid leukaemia with recurrent genetic abnormalities ICD11 code: 2A60.0
INN	Cytarabine
Medicine type	Chemical agent
List type	Complementary
Formulations	**Parenteral > General injections > unspecified:** 100 mg in vial powder for injection ; 100 mg per mL in vial
EML status history	First added in 1979 (TRS 641) Changed in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Cytarabine
DrugBank	Cytarabine

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of cytarabine (100 mg/mL in vial) to the EML and EMLc.